Relmada Therapeutics is a clinical-stage company focused on developing therapies for chronic pain. The company closed an $8M Series A financing to continue development of its product pipeline and for general corporate activities. Led by CEO Sergio Traversa and based in New York City, Relmada's lead programs include LevoCap ER, an abuse-resistant once-a-day sustained-release formulation of levorphanol slated to enter Phase III, and d-methadone, an NMDA receptor antagonist for diabetic painful neuropathy planned for Phase IIb. Additional programs include BuCap, an oral dosage form of buprenorphine set to start pilot PK studies, and MepiGel, an FDA Orphan Drug-designated topical formulation of mepivacaine beginning pilot PK studies. The company remains clinical-stage and is focused on advancing these candidates through the indicated next-stage trials. Relmada Therapeutics is a clinical-stage company based in Blue Bell, PA, developing novel therapies for the treatment of chronic pain. The company is advancing LevoCap, a once-a-day extended-release dosage form of the opioid levorphanol formulated in a tamper-resistant delivery system for patients where non-opioids or other opioids do not provide adequate relief. Relmada raised $3M in an initial close of its Series A financing. Noteholders BioAdvance and Ben Franklin Technology Partners of Southeastern Pennsylvania, along with equity investor Wonpung Mulsan Co., Ltd, converted existing liens into Series A Convertible Preferred Stock. The company intends to use the capital to continue development of LevoCap and for general corporate activities. Leadership cited in the filing includes CEO Sergio Traversa, President and CSO Najib Babul, PharmD, and Consulting Senior VP Danny Kao, PhD, JD.

Total raised

$11M

Funding rounds

2

Latest round

Series A

Latest activity

Oct 2013